ABSTRACTObjectives:The inflammatory process in Crohn's disease (CD) involves the visceral fat, characterized by adipocyte hyperplasia and altered adipose tissue and serum concentrations of TNF, leptin, adiponectin and resistin. We investigated the effect of anti-TNF therapy with infliximab (IFX) on serum adipokine levels in pediatric CD.Methods:Serum concentrations of resistin (ng/ml), leptin (ng/ml), and total adiponectin (μg/ml) were assessed by ELISA in 18 pediatric CD patients (mean age 15.0 ± 1.5 years) before 1st, 2nd and 4th IFX infusion (week 0, 2 and 14) and compared with baseline values from sex- and BMI-matched healthy controls (HC, mean age 13.4 ± 1.6 years).Results:At baseline CD patients (mean age 15.0 ± 1.5 years, 10/18 males) compared to HC (13.4 ± 1.6 years, 7/15 males) had higher resistin levels (median 14.7 ng/ml, range 5.1–50.5 vs. 7.3 ng/ml, 0.5–14.5) (p = 0.0002). At week 2 and 14 resistin decreased to 6.9 ng/ml (2.9–16.8) (p
from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2DrCt3c
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.